Brief: Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine
18/12/2025 13:30
Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O: COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026 Source text: ID:nGNXkBgFB Further company coverage: COCP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway